Over the last decade, autologous CAR-T therapy has revolutionized the treatment of hematological tumors as reflected in six different CAR-T treatments that have received marketing authorization so far to treat multiple myeloma (MM) and CD19+ B cell malignancies, and are now routinely used in the clinic (1–7). The gene discussed is CD19; the disease is hematopoietic and lymphoid cell neoplasm.